GE-BAC partner to launch LambdaFabSelect bioprocess affinity resin

GE Healthcare, the healthcare business of GE (NYSE: GE) and BAC BV, the leading provider of antibody-based affinity purification technology, announced today that, following a successful collaboration between the two companies, GE Healthcare Life Sciences has added a new and innovative affinity resin to its portfolio of technologies for the purification of antibody-based fragments. GE Healthcare's new resin, LambdaFabSelect, is a designed tool for the GMP-regulated purification of antibodies and antibody fragments that contain a lambda light chain. Antibody fragments are receiving increased attention as potential future biopharmaceuticals because, compared with monoclonal antibodies, they have a number of advantages such as improved tissue penetration and the ability to bind to targets inaccessible to conventional antigen-binding sites.

“LambdaFabSelect enables bioprocess engineers to use BAC's ligand technology to produce Fab fragments with a lambda light chain for clinical and commercial use. It provides greater flexibility in the purification of these important biotherapeutics”

The launch of LambdaFabSelect follows the success of KappaSelect an affinity resin developed in an earlier collaboration between BAC and GE Healthcare. KappaSelect is designed for the purification of antibodies and antibody fragments containing the kappa light chain.

"Henrik Ihre, Director of Custom Design Media at GE Healthcare Life Sciences, said, "One of the key challenges in antibody and antibody fragment purification is to design resins that are highly-selective and can cover a broad range of different antibody formats. Collaborating with the team at BAC has resulted in a ready-to-use product for all human antibody formats containing a lambda light chain."

"LambdaFabSelect enables bioprocess engineers to use BAC's ligand technology to produce Fab fragments with a lambda light chain for clinical and commercial use. It provides greater flexibility in the purification of these important biotherapeutics", added Laurens Sierkstra, CEO of BAC, "and complements the products we have already launched with GE Healthcare for antibody and antibody fragment purification, KappaSelect and IgSelect."

Source GE Healthcare